Arch Biopartners, Inc.

Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board